Akeso vs Merck: China’s Lung Cancer Showdown Nobody Asked For
Akeso, the Chinese biotech underdog, decided to keyboard-warrior challenge Merck’s cancer titan Keytruda with its own lung cancer drug—because what the world needed was another medical cage match. They boldly claimed increased patient survival, which is nice, but how much longer can we use ‘survival’ as a marketing pitch without sounding like a reality TV show eviction notice? Details like trial timelines, money spent, and precise survival rates were mercifully absent—maybe next press release. Meanwhile, in some lab somewhere, a scientist is probably wondering why their name isn’t in this brief yet operatic drama.
Share the Story
Nothing says biotech bragging rights like promising to out-survive Merck's star drug while leaving everyone guessing the fine print. The lung cancer weapon race now has a new player, and surprisingly, no one flinched. Medical turf wars: battle royale edition.
China’s Akeso crashing Merck’s cancer party with some vague survival talk. Watch as pharmaceutical diplomacy turns into a gladiator match, minus the lions but double the patent battles.
Akeso just whispered ’survival’ louder than Merck’s Keytruda, proving in biotech PR that shouting hopeful words sometimes counts more than numbers. Meanwhile, patients wait for footnotes.
Source: Statnews | Published: 8/26/2025 | Author: Jonathan Wosen
More Articles in Health
Sydney Sweeney's $1M Flop, Trump-Approved Jeans & Bathwater Soap Fiasco
Digital Nomad Trapped in Lisbon FOMO, Ends Up BFF Ghosted
Traveler Confirms Small Towns Are America’s Scenic Waiting Rooms
Mom Skips Junior Year Exams, Swaps Algebra for Penguins in Antarctica
America Solves Fentanyl Crisis by Inventing Pink Cocaine Zombie Apocalypse
French Obesity Rate Mystifies US After Cheese, Wine, Bread Diet Approved
Woman Waited Years to Wear Favorite Clothes; Life Finally Happened, Clothes Revolted
RFK Jr. Promises To Investigate Ultra-Processed Junk Food but Won't Regulate It
